Healthcare / BiotechnologyNasdaqCM
$1.36
-0.12 (-8.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-8.4M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$26M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-202.7%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-12.5M · FCF $-9.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Net Income | $-12.5M | $-12.5M | $-8.2M | $-8.1M | $-11.4M | $-14.3M | $-7.2M | $-7.7M | $-2.5M | — |
| EBITDA | $-12.4M | $-12.4M | $-8.2M | $-8.0M | $-11.1M | — | — | — | — | — |
| EPS | — | — | -1.28 | -2.38 | -9.50 | -16.02 | — | — | — | — |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | — | — | — | — | — | — |
| Current Ratio | 4.72 | 4.72 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-9.8M | $-9.8M | $-7.0M | $-8.4M | $-9.4M | — | — | — | — | — |
| Returns | ||||||||||
| ROE | -202.7% | -202.7% | -119.0% | -85.0% | -222.0% | -144.8% | -154.9% | -321.6% | -1610.4% | — |
| Valuation | ||||||||||
| P/B | 3.43 | 3.43 | 0.72 | 0.49 | 1.47 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| EPS Growth | — | — | 46.2% | 74.9% | — | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+61.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.28 → n/d
Residual
+61.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.